Close Close

Life Health > Life Insurance

Allergan CEO lays out plan to buck trend of rising drug prices

Your article was successfully shared with the contacts you provided.

(Bloomberg) — Allergan PLC laid out a plan to curb price increases on its drugs in response to public outcry over the costs of medication industrywide, most recently revolving around the price of Mylan NV’s EpiPen.

Related: Mylan Plans generic EpiPen to quell outcry over $600 cost

Allergan will raise prices on its products only once a year, and increases will be limited to the single-digit percentage range, Chief Executive Officer Brent Saunders said in a blog post on the company’s website. That should limit overall increases on prices to no greater than “slightly above” the current rate of inflation, he said.

The pharmaceutical industry has a “social contract” with patients, including an understanding that drugs should be priced to be accessible while providing profits to fuel research and development, Saunders said. Mylan has become the target of Washington lawmakers and public outrage after raising the price of EpiPen, used to quell life-threatening allergic reactions, by more than 400 percent since acquiring the drug in 2007.

“I understand the public outcry and add my voice to the condemnation,” of dramatic price increases on life-saving medicines, Saunders said in the post. “Those who have taken aggressive or predatory price increases have violated this social contract!”

Allergan, based in Dublin and with executive offices in New Jersey, makes branded drugs including Viberzi, a treatment for irritable bowel syndrome, and Botox, the anti-wrinkle injection. The company will not raise prices dramatically on drugs that are about to lose patent protection and face generic competition, unless it has made investments that would justify such an increase, Saunders said. The drugmaker will also spend “billions” on research and development, he said, without specifying an exact amount.


Pfizer, Allergan $160 billion deal killed by U.S. tax rules

Merck CEO says drug-price debate doesn’t account for R&D risks

Have you followed us on Facebook?


© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.